IRCT20210103049925N1
Not yet recruiting
Phase 1
Therapeutic and immunogenic effects of implanting Wharton’s jelly-derived mesenchymal stem cells into the knee joint of osteoarthritis patients in grade 2 & 3 Kellgren Lawrence scale: an interventional randomized double-blind placebo controlled clinical trial, phase I
Celltech Pharmed Company0 sites40 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Osteoarthritis.
- Sponsor
- Celltech Pharmed Company
- Enrollment
- 40
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Knee osteoarthritis (OA) (grade 2 \& 3 Kellgren Lawrence scale)
- •Radiography indicative of knee and femur malalignment of less than 30 degree
- •Pain level of 4\-7 measured in visual analog scale (VAS) 24 hours prior to referral
- •Age range of 40\-65 years
- •Female/Male
- •Given informed consent
Exclusion Criteria
- •Inflammatory disorders
- •Metabolic disorders (e.g : diabetes mellitus)
- •Autoimmune diseases
- •Immunodeficiency
- •Cancer or other severe diseases
- •Contagious viral infections
- •Psychological disorders
- •History of renal or hepatic failure
- •Body mass index (BMI) \>30
- •Oral corticosteroids in the last 4 weeks
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patientsMetastatic Cutaneous and Subcutaneous MelanomaMedDRA version: 15.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002059-40-ITISTITUTO NAZIONALE PER LA CURA TUMORI
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-002554-23-ITOCTAPHARMA AG108
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-002554-23-PLOCTAPHARMA AG108
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 15.1Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-002554-23-ESOCTAPHARMA AG100
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 18.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-002554-23-HROCTAPHARMA AG108